Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteventurefund.novar...
Phone+41 61 324 32 67
Emailsimone.forrer@nov...
Employees
Founded1996
Descriptioninvestment management

Funds

Offices

HQ
Novartis International AG, Forum 1-3.73
Basel, CH-4002, CHE
Cambridge, USA
Five Cambridge Center
Cambridge, MA, 02142
USA

People

Founder and Chairman
General Partnerr
Managing Director
Managing Director
Managing Director
Managing Director
Managing Director
Chief Financial Officer
Show All People

Tags

Novartis Venture Fund

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.

We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company’s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 15 – 20 mio per company over its life, but it can be as little as 100’000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates.

Sectors

New therapeutics & platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography

USA/Canada Europe Switzerland Asia/Pacific

Recent Milestones

Investments

Company Date Round Size Participants
Alios BioPharma 4/2014Series B$41M4
Neurovance 4/2014Series A$6.3M8
Thesan Pharmaceuticals 2/2014Series B$49M4
Covagen 12/2013Series B$47.2M8
Aileron Therapeutics 11/2013Series E$30M6
Merus 10/2013Series B€31M5
Opsona 10/2013Series C€3M9
Akebia Therapeutics 6/2013Series C$41M9
Effector Therapeutics 5/2013Venture Round$45M7
Tokai Pharmaceuticals 5/2013Series E$35.5M2
Opsona 4/2013Series C€33M8
Advanced Animal Diagnostics 4/2013Series B$6M2
GenSight Biologics 4/2013Series A€32M4
Catalyst Biosciences 4/2013Venture Round$5.07M6
Aileron Therapeutics 1/2013Series D$12M6
Galera Therapeutics 12/2012Series A$11M3
Bicycle Therapeutics 12/2012Venture Round£3.75M5
Thesan Pharmaceuticals 10/2012Series A$16M2
F2G 9/2012Venture Round$30M6
Aerpio Therapeutics 8/2012Series A$27M6
Sorbent Therapeutics 8/2012Partial Close$18.1M3
ImaginAb 3/2012Series A$12.5M3
BioRelix 3/2012Venture Round$2.56M4
Celladon 2/2012Venture Round$43M6
Akebia Therapeutics 1/2012Series B$4.1M7
Tokai Pharmaceuticals 9/2011Series D$23M2
Pulmatrix 8/2011Series B$14M4
Atlas Genetics 7/2011Series B£16.9M5
MyoPowers Medical Technologies 7/2011Series B$16M3
Sorbent Therapeutics 6/2011Series B$36M5
Akebia Therapeutics 4/2011Series B$22M7
ProCertus BioPharm 4/2011Series A$1.7M1
Advanced Animal Diagnostics 3/2011Series B$11M2
Euthymics Bioscience 3/2011Series A$4M4
Covagen 11/2010Series A$6.3M5
Cylene Pharmaceuticals 9/2010Series D$12M6
Anchor Therapeutics 8/2010Series B$10M3
Foldrx Pharmaceuticals 6/2010Venture Round$29M7
NanoPowers 6/2010Series A$4.5M3
Immune Targeting Systems 3/2010Series A$13.2M4
Merus 1/2010Series B€21.7M4
Cellerix 1/2010Series C$37.7M6
Nabriva Therapeutics 1/2010Series B$22M4
MicroCHIPS 1/2010Venture Round$16.5M9
FORMA Therapeutics 12/2009Series B$3M3
Evolva 12/2009Series B$16M7
GlycoMimetics 12/2009Series C$38M5
FORMA Therapeutics 12/2009Series B$25.5M3
Oxagen 11/2009Series C$26.7M9
Cellerix 11/2009Series B€27M6
Pulmatrix 11/2009Series B$30.2M4
Covagen 10/2009Seed2
PharmAbcine 9/2009Series A$6M4
Akebia Therapeutics 9/2009Series A$16M5
LigoCyte Pharmaceuticals 8/2009Series C$29.5M4
Intellikine 7/2009Series B$51M6
Viamet Pharmaceuticals 7/2009Series B$25M6
Opsona 6/2009Series B$4.6M6
Aileron Therapeutics 6/2009Series D$40M6
Alios BioPharma 6/2009Series A$8M3
Tokai Pharmaceuticals 6/2009Series D$22M2
NovImmune 5/2009Series C$54.8M7
Visiogen 5/2009Series D$40M7
Alios BioPharma 2/2009Series A$24M3
Intradigm Corporation 1/2009Series B$21.4M8
Diagnoplex 12/2008Series A$8.3M2
Catalyst Biosciences 12/2008Series C$40M7
Proteostasis Therapeutics 8/2008Series A$70.6M5
ESBATech 8/2008Series B$22M7
Biofisica 4/2008Venture Round$2.3M3
Aileron Therapeutics 4/2008Series B$10.5M2
FORMA Therapeutics 4/2008Series A$4M1
Ascent Therapeutics 11/2007Series A$19M3
Neovacs 7/2007Venture Round€13M2
Cequent Pharmaceuticals 6/2007Series A$9M4
BioRelix 6/2007Series A$25.8M6
Tepha 6/2007Series B$10.7M4
Phenomix 3/2007Series C$55M10
Trellis Bioscience 2/2007Series B$10M4
Omeros 2/2007Series E$63M8
Aileron Therapeutics 12/2006Series A$7M2
Intradigm Corporation 11/2006Series A$16M5
Biofisica 10/2006Series A$5M3
ESBATech 8/2006Series B$41M7
NovImmune 6/2006Series B$46M5
Viron Therapeutics 5/2006Series A$20M6
Catalyst Biosciences 2/2006Series B$30M6
EraGen Biosciences 1/2006Series A$12M4
PTC Therapeutics 11/2005Private Equity$26.6M9
Covalys Biosciences 2/2005Series B$2.59M3
NovImmune 5/2000Series A$14M2

Videos

Sources

  1. Alios BioPharma Completes $41M Series B Financing (finsmes.com) [edit]
  2. Neurovance Raises $6.3M Extension in Series A1 Round (finsmes.com) [edit]
  3. Thesan Pharmaceuticals Closes $49M Series B Financing (finsmes.com) [edit]
  4. Gimv leads Series B round for Covagen (pehub.com) [edit]
  5. Aileron Therapeutics Secures $30M in Series E Equity Financing (finsmes.com) [edit]
  6. Merus Raises €31M in Series B Financing (finsmes.com) [edit]
  7. Opsona Therapeutics Raises €3M Series C Equity Financing (finsmes.com) [edit]
  8. Akebia Therapeutics Completes $41M Series C Financing (finsmes.com) [edit]
  9. Effector Therapeutics snags $45M venture round from A-list backers (fiercebiotech.com) [edit]
  10. Tokai lands $35M venture round for triple-threat prostate cancer drug (fiercebiotech.com) [edit]
  11. Opsona Therapeutics Raises €33M in Series C Financing (finsmes.com) [edit]
  12. Advanced Animal Diagnostics Closes $6M Tranche of Series B Financing (finsmes.com) [edit]
  13. GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy (finance.yahoo.com) [edit]
  14. VC Funding: Q2 2013 source [edit]
  15. Aileron Therapeutics Raises $12M in Series D Financing (finsmes.com) [edit]
  16. Galera Therapeutics Raises $11 Million in Series A Financing (in.finance.yahoo.com) [edit]
  17. Bicycle Therapeutics Raises £3.75M in Funding (finsmes.com) [edit]
  18. Thesan Pharmaceuticals Closes $16M Series A Financing (finsmes.com) [edit]
  19. F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds (fiercebiotech.com) [edit]
  20. Aerpio Therapeutics Closes $27M Series A Financing (finsmes.com) [edit]
  21. SEC (sec.gov) [edit]
  22. ImaginAb Completes $12.5M Series A Financing (finsmes.com) [edit]
  23. Connecticut biotech raises $2.56M round (masshightech.com) [edit]
  24. Celladon Closes $43M in Funding (finsmes.com) [edit]
  25. Akebia Therapeutics Raises $4.1M in Series B Financing (finsmes.com) [edit]
  26. Tokai Pharmaceuticals Raises $23 Million in Funding (eon.businesswire.com) [edit]
  27. Pulmatrix Secures a $14 million Financing to Advance Clinical Programs in COPD and Cystic Fibrosis (eon.businesswire.com) [edit]
  28. Atlas Genetics Ltd Completes £16.9 million Series B Financing led by Novartis Venture Funds (atlasgenetics.com) [edit]
  29. MyoPowers Medical Technologies Closes CHF16M Series B Financing Round (finsmes.com) [edit]
  30. Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million (money.msn.com) [edit]
  31. AKEBIA COMPLETES $22M SERIES B FINANCING (akebia.com) [edit]
  32. ProCertus BioPharm secures $1.7 million in financing (procertus.com) [edit]
  33. Advanced Animal Diagnostics Raises $11 Million in Equity Financing (advancedanimaldiagnostics.com) [edit]
  34. Euthymics Bioscience bumps Series A to $28M (masshightech.com) [edit]
  35. Covagen closes Series A financing round with Seroba Kernel as lead investor (covagen.com) [edit]
  36. Cylene Pharmaceuticals Gets $12M (socaltech.com) [edit]
  37. Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates (anchortx.com) [edit]
  38. FoldRx banks $29M for neurodegenerative drug application (fiercebiotech.com) [edit]
  39. NanoPowers raises CHF 5 million ($4.5 million) (nanopowers.ch) [edit]
  40. Immune Targeting Systems, Ltd.: Series A $13.2 (onbiovc.com) [edit]
  41. Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund (merus.nl) [edit]
  42. Cellerix, SL: Series C $37.7M (onbiovc.com) [edit]
  43. Nabriva Therapeutics, AG: Series B $22M (onbiovc.com) [edit]
  44. MicroCHIPS Raises $16.5M in Equity Financing (finsmes.com) [edit]
  45. Forma Therapeutics lands $3M in equity (masshightech.com) [edit]
  46. Evolva Goes Public In Reverse Merger, Raises $43M (fis.dowjones.com) [edit]
  47. GlycoMimetics, Inc.: Series C $38M (onbiovc.com) [edit]
  48. AltAssets (altassets.com) [edit]
  49. Oxagen rounds up $26.7M in VC (fiercebiotech.com) [edit]
  50. Cellerix closes €27,2m financing round to bring product Cx401 to market (cellerix.com) [edit]
  51. Xconomy Boston (xconomy.com) [edit]
  52. Covagen (covagen.com) [edit]
  53. PharmAbcine Closes USD $6 Million Series A Financing (bio-medicine.org) [edit]
  54. Akebia Therapeutics, Inc.: Series A $16M (onbiovc.com) [edit]
  55. SEC D/A (sec.gov) [edit]
  56. Intellikine, Inc.: Series B $51M (onbiovc.com) [edit]
  57. SEC (sec.gov) [edit]
  58. Opsona Therapeutics, Ltd.: Series B $4.6M (onbiovc.com) [edit]
  59. Aileron Therapeutics Closes Series D Financing (zibb.com) [edit]
  60. Alios raises another $8M (fiercebiotech.com) [edit]
  61. Tokai Pharmaceuticals, Inc.: Series D $22M (onbiovc.com) [edit]
  62. NovImmune, SA: Series C $54.8M (onbiovc.com) [edit]
  63. Visiogen, Inc.: Series D $40M (onbiovc.com) [edit]
  64. Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 (aliosbiopharma.com) [edit]
  65. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive (fiercebiotech.com) [edit]
  66. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing (bio-medicine.org) [edit]
  67. Catalyst Biosciences Raises $40 Million in Series C Financing (fiercebiotech.com) [edit]
  68. SEC (sec.gov) [edit]
  69. ESBATech rounds up $22M in second round (fiercebiotech.com) [edit]
  70. Capital Funding Report [edit]
  71. Aileron ramps up business on heels of positive results (boston.bizjournals.com) [edit]
  72. Forma raised $4 million in a Series A (masshightech.com) [edit]
  73. SEC (sec.gov) [edit]
  74. Neovacs, a leading biotech company in the field of therapeutic vaccines in oncology and inflammatory diseases, raises 13 million Euros from a international group of specialist investors, including the Novartis Venture Fund and Truffle Capital (neovacs.fr) [edit]
  75. Cequent Pharmaceuticals (cequentpharma.com) [edit]
  76. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
  77. Tepha, Inc. Announces $10.7 Million Venture Capital Financing (tepha.com) [edit]
  78. PHENOMIX COMPLETES $55 MILLION SERIES C FINANCING (phenomixcorp.com) [edit]
  79. Trellis Bioscience, cell monitoring company, raises $10M (venturebeat.com) [edit]
  80. Omeros Raises More Than $63 Million in Financing (investor.omeros.com) [edit]
  81. Aileron scores $7M in new venture funds (fiercebiotech.com) [edit]
  82. INTRADIGM ANNOUNCES SIGNIFICANT ENHANCEMENTS OF THE COMPANY CAPABILITIES, A NEW SERIES A FINANCING AND IMPORTANT ADDITION TO SENIOR MANAGEMENT TEAM (intradigm.com) [edit]
  83. ATLANTA-BASED BIOFISICAâ„¢ RECEIVES $5 MILLION IN SERIES A FINANCING (biofisica.com) [edit]
  84. ESBATech Closes USD 41M Series B Venture Financing (esbatech.com) [edit]
  85. Series B funding round raises CHF 58 million (novimmune.com) [edit]
  86. Viron Therapeutics raises US $20 million (vironinc.com) [edit]
  87. CATALYST BIOSCIENCES RAISES $30 MILLION SERIES B FINANCING TO ADVANCE THERAPEUTIC PROTEASES (catalystbiosciences.com) [edit]
  88. EraGen (eragen.com) [edit]
  89. PTC THERAPEUTICS RAISES $26.6 MILLION IN PRIVATE PLACEMENT FINANCING (ptct.client.shareholder.com) [edit]
  90. EDGAR [edit]
  91. Company History (novimmune.com) [edit]
Edit This Page
Last Edited 4/7/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy